A detailed history of Impax Asset Management Group PLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Impax Asset Management Group PLC holds 470,603 shares of PCRX stock, worth $7.85 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
470,603
Previous 470,603 -0.0%
Holding current value
$7.85 Million
Previous $7.09 Million -0.0%
% of portfolio
0.03%
Previous 0.03%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$11.7 - $28.46 $2.46 Million - $5.99 Million
210,576 Added 80.98%
470,603 $7.09 Million
Q2 2024

Nov 08, 2024

SELL
$25.5 - $31.51 $5.37 Million - $6.64 Million
-210,576 Reduced 44.75%
260,027 $7.44 Million
Q1 2024

Apr 30, 2024

BUY
$27.7 - $35.48 $1.66 Million - $2.13 Million
60,000 Added 30.0%
260,027 $7.6 Million
Q4 2022

Feb 09, 2023

SELL
$38.19 - $57.45 $2.67 Million - $4.02 Million
-70,000 Reduced 25.92%
200,027 $7.72 Million
Q2 2022

Aug 11, 2022

SELL
$51.49 - $81.64 $772,350 - $1.22 Million
-15,000 Reduced 5.26%
270,027 $15.7 Million
Q1 2022

May 16, 2022

BUY
$60.03 - $76.49 $1.57 Million - $2 Million
26,091 Added 10.08%
285,027 $21.8 Million
Q4 2021

Feb 14, 2022

BUY
$47.97 - $62.21 $2.83 Million - $3.66 Million
58,909 Added 29.45%
258,936 $15.6 Million
Q3 2021

Nov 12, 2021

BUY
$54.64 - $61.3 $1.64 Million - $1.84 Million
30,000 Added 17.64%
200,027 $11.2 Million
Q2 2021

Aug 05, 2021

BUY
$59.18 - $69.99 $2.66 Million - $3.15 Million
45,027 Added 36.02%
170,027 $10.3 Million
Q1 2021

May 14, 2021

BUY
$59.31 - $78.82 $7.41 Million - $9.85 Million
125,000 New
125,000 $8.76 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $764M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Impax Asset Management Group PLC Portfolio

Follow Impax Asset Management Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Impax Asset Management Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Impax Asset Management Group PLC with notifications on news.